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ABSTRACT
Human nuclear uracil DNA glycosylase (UNG2) is a
cellular DNA repair enzyme that is essential for a
number of diverse biological phenomena ranging
from antibody diversification to B-cell lymphomas
and type-1 human immunodeficiency virus infectiv-
ity. During each of these processes, UNG2 recog-
nizes uracilated DNA and excises the uracil base by
flipping it into the enzyme active site. We have taken
advantage of the extrahelical uracil recognition
mechanism to build large small-molecule libraries
in which uracil is tethered via flexible alkane linkers
to a collection of secondary binding elements. This
high-throughput synthesis and screening approach
produced two novel uracil-tethered inhibitors of
UNG2, the best of which was crystallized with the
enzyme. Remarkably, this inhibitor mimics the
crucial hydrogen bonding and electrostatic interac-
tions previously observed in UNG2 complexes with
damaged uracilated DNA. Thus, the environment of
the binding site selects for library ligands that share
these DNA features. This is a general approach to
rapid discovery of inhibitors of enzymes that
recognize extrahelical damaged bases.
INTRODUCTION
The RNA base uracil is one of the most prevalent non-
canonical bases found in genomic DNA (1). It arises from
spontaneous or intentional enzymatic deamination of cytosine
in DNA (2–5), or alternatively, by misincorporation of dUTP
in place of TTP during DNA replication (6). Both pathways
for uracil incorporation are forms of DNA damage, and
accordingly, an elaborate uracil base excision repair
(UBER) mechanism is present in all organisms to reverse
this damage (Figure 1A) (7). Without repair, U/G mismatches
lead to T/A transition mutations and corresponding changes
in protein sequence. Although U/A base pairs arising from
misincorporation of dUTP are not mutagenic, if large num-
bers of uracils are inserted on both strands of replicated
DNA this can lead to disruptions in gene expression, and
even double strand DNA breaks can arise from the base exci-
sion repair process (8). Although the accidental appearance of
uracil in DNA is well-appreciated, it has become apparent
that enzymatic deamination of cytosine to uracil in DNA
plays a key role in the processes of somatic hypermutation
and class switch recombination in B cells (2,9,10), in certain
B cell lymphomas (11), and as an innate host defense mecha-
nism against retroviral infection (12). In addition, the widely
used chemotherapeutic agent 5-ﬂuorouracil (5-FU) promotes
uracil misincorporation into DNA by increasing the ratio
[dUTP]/[TTP] in the cell, suggesting inhibitors of UBER
could serve as sensitizers during 5-FU therapy (8,13). In gen-
eral, these diverse roles for uracil indicate that small molecule
UBER inhibitors might be very useful investigational or
therapeutic agents.
In humans, the ﬁrst step in the UBER pathway, cleavage of
the glycosidic bond of deoxyuridine in DNA, is catalyzed by
the powerful nuclear enzyme uracil DNA glycosylase
(UNG2) (14). This extensively studied glycosylase uses an
extrahelical recognition mechanism in which the uracil base
that is originally embedded in the DNA base stack is ulti-
mately extruded into the enzyme active site (Figure 1B)
(15). Thus by ‘uracil ﬂipping’ the enzyme can recognize
the unique structural features of uracil that allows catalysis
to proceed (7). Although the uracil is attached to a large
duplex DNA substrate, most of the enzyme–substrate interac-
tions involve the base itself. Perhaps not surprisingly, the
uracil base alone has been found to be a product inhibitor
of the enzyme (Ki   300 mM at physiological pH) (16).
We recently published a general strategy for rapid discov-
ery of small molecule inhibitors of UNG2 and other UBER
enzymes called ‘substrate fragment tethering’ (SFT) (17),
which is an efﬁcient variation of the combinatorial target-
guided ligand assembly method of Ellman et al. (18). The
basic approach is extremely simple and involves tethering a
chemical library of aldehydes to pieces of substrates (such
as uracil) that already bind weakly to an enzyme active
site. As shown in Figure 2, UNG2 library synthesis involves
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lent alkyloxyamine linker, a uracil aldehyde derivative, and
each library aldehyde member. Thus, the uracil fragment tar-
gets the entire tethered molecule to the active site where the
library pieces can then explore adjacent binding pockets. SFT
has the following strengths: (i) library synthesis is economi-
cal and very rapid and can be performed in microtiter plate
format, (ii) the reactions are extremely efﬁcient and no puri-
ﬁcation of any products is required, (iii) mixtures of ﬂexible
linkers are used in each reaction which allows multiple teth-
ering lengths to be probed simultaneously in activity screens,
and (iv) the method is easily adaptable to any desired target.
Here we report the results from high-throughput screening
(HTS) of an SFT library derived from tethering 6-formyl
uracil to a library of 215 different aldehyde-binding elements.
Of the two hits identiﬁed in this screen, the most potent SFT
ligand was co-crystallized with UNG2 to yield a high-
resolution structure of the complex. This ﬁrst portrait of a
bound SFT ligand shows how a small molecule can surpris-
ingly mimic the hydrogen bonding and electrostatic interac-
tions of a larger DNA substrate. Thus, the environment of
the binding site appears to select for library ligands that
share molecular features of DNA. This efﬁcient approach
should be easily adaptable to other DNA repair glycosylases
that recognize extrahelical bases.
MATERIALS AND METHODS
Reagents and general methods
All chemicals were purchased from commercial sources with-
out further puriﬁcation unless otherwise stated. The
1H NMR
spectra were recordedon a400MHz VarianInnova instrument
in hexadeuteriodimethylsulfoxide (DMSO-d6). The chemical
shifts of protons are given in p.p.m. with DMSO as an internal
standard.
Synthesis of tethered oxime libraries
The 6-formyluracil tethered library was synthesized as
described previously (17). Brieﬂy, a set of 215 alkyl and
aryl aldehydes (Supplementary Table S1) was selected for
library synthesis and coupled to 6-formyluracil using the
O,O0-diaminoalkanediol linkers as follows. To each 0.5 ml
well of a Matrix microtiter plate was added a DMSO stock
solution of AcOH (20 ml, 150 mM, 3 mmol), 6-formyluracil
(20 ml, 150 mM, 3 mmol) and a single alkyl or aryl aldehyde
(20 ml, 150 mM, 3 mmol). The plate was carefully agitated to
make the solutions homogenous. To each of the mixtures was
added a DMSO solution of the O,O0-diaminoalkanediol link-
ers containing each of the ﬁve linker lengths in equal propor-
tion (22 ml, 150 mM, 3.3 mmol total amine equivalents). The
plate was sealed, further agitated and incubated in an oven
for 12 h at 37 C.
Deconvolution of inhibitory mixtures
The two active mixtures containing compounds 1 and 2 were
deconvoluted with respect to linker length by individually
synthesizing each oxime dimer using a single diaminoalkane-
diol linker per reaction. At this stage we did not separate
the homodimers from the heterodimers in the mixtures. The
linker length dependence of the inhibition is reported in Sup-
plementary Table S2. The corresponding compounds were
then synthesized in larger scale and puriﬁed for complete
analysis of their inhibition properties as described below.
Figure 1. Uracil DNA base excision repair and extrahelical recognition of
uracil. (A) Uracil in the context of a U/A or U/G base pair is repaired by a
series of enzymatic reactions that restore the integrity of the DNA sequence.
The first enzyme in the pathway is uracil DNA glycosylase (UNG) that
hydrolytically cleaves the N-glycosidic bond connecting the uracil to the
deoxyribose, leaving an abasic site and free uracil. Three other enzymes
complete the repair process in humans: an abasic site endonuclease (APE1), a
dual-function repair polymerase (pol b) that inserts the correct nucleotide and
eliminates the abasic site via a b-elimination reaction, and finally, DNA
ligase. (B) Structure of uracilated DNA bound to human UNG2 (PDB code
1EMH).
Figure 2. Chemistry of substrate fragment tethering. In this approach, a
suitable substrate fragment (such as uracil) is identified and derivatized at a
nonperturbing position with an aldehyde functional group. In the case of
UNG2, the substrate fragment ii 6-formyluracil. The substrate fragment is
tethered to one end of a bifunctional alkyloxyamine linker of variable length
(n ¼ 2–6), which is thenderivatized on the other end with a library of aldehyde
bindingelements(RCHO).Althoughstatisticalmixturesofallpossibleoximes
result (25% each homodimer derived from uracil-CHO or RCHO, and 50% of
the heterodimer derived from uracil-CHO and RCHO), this poses no difficulty
because the crude mixtures are directly screened for inhibitory activity. Once
active mixtures are identified, the specific inhibitory components can be
rapidly identified by deconvolution to uncover the linker length that gave rise
to the observed inhibition. The structures of the 215 aldehyde library members
used in this study are reported in Supplementary Table S1.
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Solutions (0.15 M) of 4-carboxybenzaldehyde (888 ml,
0.165 mmol), 6-formyluracil (888 ml, 0.165 mmol) and acetic
acid (888 ml, 0.165 mmol) in DMSO were added to a reaction
vessel. The reaction was initiated by the addition of 0.15 M
O,O0-diaminoethanediol (888 ml, 0.165 mmol) in DMSO, and
incubated at 37 C for 36 h. The desired heterosubstituted com-
pound was puriﬁed by direct injection of the reaction mixture
onto a Phenomenex Aqua reversed phase C-18 HPLC column
(250 mm, 10 mm, 5 mm) using gradient elution from 0 to 65%
CH3CN in 0.1 M aqueous TEAA over the course of 2 h using
UVdetectionat320nm.Fractionscontaining1werecombined
and concentrated in vacuo. The compound was precipitated
using ice-cold water, centrifuged, washed twice with ice-cold
water and dried in vacuo. This yielded 1 as a white powder
(9.6 mg, 0.028 mmol) in 34% yield.
1H NMR (400 MHz,
DMSO-d6): d 11.19 (s, 1H), 10.81 (s, 1H), 8.37 (s, 1H), 7.98
(s, 1H), 7.96 (d, 3H), 7.72 (d, 2H), 5.79 (s, 1H), 4.66 (d, 4H);
13C NMR (400 MHz, DMSO-d6): d 167.6, 163.9, 151.0,
148.7, 144.5, 142.5, 129.8, 126.9, 102.0, 73.2, 71.9; (m/z):
[M+H]
+ calcd for C15H14N4O6, 347.0986; found, 347.0991.
Synthesis of 2
The synthesis and puriﬁcation was identical to that re-
ported above for 1 except that 0.15 M solutions of
3-carboxybenzaldehyde and O,O0-diaminopropanediol were
used.
1H NMR (400 MHz, DMSO-d6): d 11.16 (s, 1H),
10.78 (s, 1H), 8.34 (s, 1H), 8.18 (s, 1H), 7.94 (d, 2H), 7.83
(d, 2H), 7.53 (t, 1H), 5.76 (s, 1H), 4.27 (t, 2H), 4.20 (t, 2H),
2.10 (m, 2H);
13C NMR (400 MHz, DMSO-d6): d 166.9,
163.9, 151.0, 148.3, 144.6, 142.2, 132.5, 131.5, 130.9,
130.5, 129.2, 127.6, 101.7, 71.8, 70.5, 28.4; (m/z): [M+H]
+
calcd for C15H14N4O6, 361.1143; found, 361.1153.
High-throughput screening of oxime library
The DNA substrate in this HTS assay was synthesized using
standard phosphoramidite DNA solid-phase chemistry using
reagents purchased from Glen Research. The DNA was puri-
ﬁed using anion exchange chromatography followed by
desalting using reversed phase methods. The sequence and
size was conﬁrmed using analytical denaturing PAGE and
MALDI-MS. The substrate is a single-stranded 28mer DNA
hairpin containing nine U·A base pairs and a hexapolyethy-
lene glycol (PEG6) linker (50-FAM-GCA CUU AAG AAU
UG-PEG6-CA AUU CUU AAG UGC-DABSYL-30). The
UNG2 HTS assay has been described previously (17).
IC50 determinations
To a 96-well plate was added 5 ml compound 1 in DMSO, fol-
lowed by 75 ml of 66.5 nM PEG-U9 hairpin in reaction buffer
(20 mM Tris–HCl, pH 8.0, 50 mM KCl, 0.2 mM MgCl2 and
0.05% Brij-35). Eight different inhibitor concentrations were
used in the range of 0.045–100 mM. Reactions were initiated
by the addition of 20 ml of 0.5 nM human UNG in reaction
buffer. The ﬁnal concentrations of reagents in the assay are
20 mM Tris–HCl, pH 8.0, 50 mM KCl, 0.2 mM MgCl2,
0.05% Brij-35, 5% DMSO, 0.1 nM human UNG, 50 nM
PEG-U9 hairpin DNA and 0–100 mM 1. Wells containing
DMSO vehicle only or no UNG2 were used as negative con-
trols and background, respectively. The plates are incubated
at ambient temperature in a ﬂuorescence plate reader for
30 min, and the progress of the reaction was monitored
every 5 min (Ex. 485 nm/Em. 520 nm). Percent inhibition
versus log concentration of 1 data were ﬁt to a four parameter
sigmoidal dose–response equation (Equation 1) using Prism
4.0 (GraphPad Software Inc., San Diego, CA, USA).
% Inhibition ¼
MinðMax   MinÞ
1 þ 10ððlogIC50 log½1 Þ*nÞ : 1
Mechanism of inhibition
To a 96-well plate was added 5 ml compound in DMSO, fol-
lowed by 75 ml PEG-U9 hairpin in reaction buffer (20 mM
Tris–HCl, pH 8.0, 50 mM KCl, 0.2 mM MgCl2 and 0.05%
Brij-35). Eight different DNA concentrations were used in
the range of 27.5–1100 nM. Reactions were initiated by the
addition of 20 ml of 0.5 nM human UNG in reaction buffer.
The ﬁnal concentrations of reagents in the assay are 20 mM
Tris–HCl, pH 8.0, 50 mM KCl, 0.2 mM MgCl2, 0.05%
Brij-35, 5% DMSO, 0.1 nM human UNG, 27.5–1100 nM
PEG-U9 hairpin DNA and 0–128 mMo f1. The plates were
incubated at ambient temperature in a ﬂuorescence plate
reader for 60 min, and the progress of each reaction was
monitored every 30 s (lex ¼ 485 nm, lem ¼ 520 nm). After-
wards, Escherichia coli UNG was added to each well to drive
the reactions to completion, and the total change in ﬂuores-
cence corresponding to complete consumption of the sub-
strate was calculated (DFUtot). These values were used to
calculate initial molar velocities (i.e. [product]/s ¼ DmM/
DFUtot · FU/s). Mechanisms of inhibition and their corre-
sponding inhibitor dissociation constants were determined
by Lineweaver–Burk slope and intercept replot analysis.
Cell culture studies
Currently, there exists no simple assay to monitor the efﬁcacy
of inhibitors of UNG within living cells. In order to evaluate
the ability of compound 1 to inhibit UNG in vivo, inhibitor
was added to cells in culture, lysates were carefully prepared
to minimize dilution of the inhibitor, and UNG activity was
assayed as follows (Figure 3). PC-3 human prostate adenocar-
cinoma cells were grown in Modiﬁed Eagle’s Medium
(Mediatech) supplemented with 10% fetal bovine serum
(Hyclone) and penicillin/streptomycin. Cells at 70% conﬂu-
ency were trypsinized, resuspended in growth media and
counted using a hemocytometer. The cells were then centri-
fuged and resuspended to a density of 1 · 10
6 cells/ml.
Aliquots of 1 · 10
6 cells were pelleted and resuspended in
46.5 ml growth media with or without 3 mM compound 1
to achieve a ﬁnal concentration of 3 mM inhibitor. The
cells were incubated at 37  C, 5% CO2 for 30 min before
being spun down and resuspended in 7 ml UNG lysate reac-
tion buffer [10 mM Tris–HCl, pH 8.0, 60 mM NaCl, 1 mM
DTT, 1 mM EDTA, 0.002% Brij 35, protease inhibitors
(Roche Complete, Mini)]. The cells were lysed by freeze-
thawing ﬁve times, the lysates were centrifuged at
14000 r.p.m. for 30 min and the supernatant was transferred
to a fresh tube, and the volume was now increased by 3.5 ml
based on the number of cells pelleted (106) and the average
cell volume of 3.5 pl for PC-3 cells (19). Thus, it is calculated
that 3.5 ml · 3 mM (1) ¼ 10 nmol of compound 1 was trapped
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the PEG-U9 hairpin substrate and 2 ml lysate in a total reac-
tion volume of 150 ml. Assuming equilibration of 1 across the
cell membrane, its ﬁnal concentration in the ﬂuorescence
reaction was 13 mM. Initial reaction velocities were calcu-
lated using the total change in ﬂuorescence as described
(1) and normalized to protein content measured using the
BioRad protein assay.
Crystallization of the complex of UNG2 and 3-(2)-A8
Human UNG2 was expressed and puriﬁed as described
previously (20). A solution of human UNG2 (112.5 ml,
44.2 mg/ml) in a buffer containing 50 mM Tris–OAc,
pH 7.0, 150 mM NaCl and 1 mM DTT, was mixed with 1
(12.5 ml, 16.8 mM) in 100 mM Tris–HCl, pH 8.0 and 5%
DMSO. The mixture was allowed to incubate at ambient
temperature for 30 min, and then centrifuged at 10000· g
for 5 min. Co-crystallization conditions were screened
using the Nextal PEG Suite library. A total of 300 nl of the
complex was mixed with an equal volume of precipitant,
and allowed to crystallize at 22 C using the hanging drop
method. Crystals were observed within 48 h with 0.2 M pot-
assium thiocyanate, 20% PEG 3350. X-ray diffraction data
were collected from a ﬂash frozen crystal in its unmodiﬁed
mother liquor at the National Synchrotron Light source at
Brookhaven National Laboratory (beam line X6A) using a
wavelength of 1.1 s with a ADSC CCD detector Quantum-
4. The package HKL2000 (21) was used for data reduction.
The structure was determined by molecular replacement
with the program MOLREP using the uncomplexed UNG2
structure (1KHZ) as the searching model. After an initial
rigid-body reﬁnement, compound 1 was placed in a difference
Fourier electron density. The ﬁnal model of the UNG2-1
complex, reﬁned using REFMAC5 (22) with isotropic tem-
perature factors, shows all non-glycine residues in allowed
regions of the Ramachandran plot and excellent stereochem-
istry (Table 1). Riding hydrogens of protein atoms were
used in REFMAC5. The structural statistics are reported
in Table 1.
RESULTS AND DISCUSSION
We previously used SFT to identify two uracil-tethered
inhibitors of UNG2 from a small aldehyde library containing
only 14 different aldehyde binding elements (17). Although
these SFT compounds had Ki values between 0.3 and
3 mM, the non-uracil binding elements were derived from
unstable di- or trihydroxybenzaldehydes. Thus, these initial
compounds were prone to air oxidation to the inactive qui-
none forms, and were not suitable for structural or cell culture
studies. We therefore turned to screening a much larger
215 member aldehyde library using our high-throughput
molecular beacon ﬂuorescence assay (see Supplementary
Data) (17). This screening effort resulted in the identiﬁcation
of two new active mixtures (Figure 4). After deconvolution
to identify the linker length that gave rise to inhibition, and
puriﬁcation of the individual inhibitory compounds, the IC50
values were determined (Figure 5A).
The library binding elements that gave rise to the observed
inhibition shared a common chemical structure The two most
potent compounds 1 and 2,w i t hI C 50 values of 9 and 11 mM,
respectively, both shared formate-substituted benzaldehyde
functional groups and short alkyl chain linker lengths of
n ¼ 2 or 3 (Figure 4). These structure-activity trends sug-
gested the presence of a binding pocket directly adjacent to
the uracil binding site that depends on positioning of the
negatively charged formate groups of either 1 or 2. To date,
tethering library binding elements to the 6-formyl uracil
substrate fragment has brought about increases in binding
afﬁnity of up to  3 kcal/mol as compared to the O-methyl
Figure 3. Assay for small molecule inhibition of UNG in cells.
Nucleic Acids Research, 2006, Vol. 34, No. 20 5875oxime derived from 6-formyl uracil and methoxyamine
(Ki ¼ 45 mM) (17).
Since 1 showed the highest activity we investigated its
mode of inhibition in greater detail. Interestingly, most of
our previously reported SFT inhibitors, as well as the uracil
base itself, showed surprisingly complex modes of inhibition
with either competitive or partial uncompetitive binding to
two distinct uracil binding sites (17). This surprising
complexity, which is not entirely understood at a structural
level, was attributed to the presence of a second weak uracil
binding site that may be occupied transiently during the
process of uracil ﬂipping into the active site. In contrast
with the previous complexity, the inhibition patterns for
1 indicated simple competitive inhibition (Figure 5B), with
linear Lineweaver–Burk slope replots (data not shown).
SFT inhibitor 1 also showed an IC50 value against full-length
UNG2 that was only 25% greater than the catalytic domain
(the full length UNG2 was assayed using cell extracts). The
full-length UNG2 protein differs from the catalytic domain
by a 90 amino acid N-terminal extension that is involved in
nuclear localization and other protein interactions (23).
Thus, mode of inhibition analysis indicates that 1 competes
for binding to the extrahelical uracil binding site observed
in the uracilated-DNA complex shown in Figure 1B and
that its inhibitory potency is not affected by the N-terminal
extension present in nuclear UNG2.
We also investigated the potency of 1 in cell culture. Since
there is no simple marker for assessing UNG2 inhibition in
cell culture, an ex vivo assay was developed to assess whether
the inhibitor enters cells and binds to UNG2. In this assay,
cells are treated with a single high concentration of inhibitor
(3 mM), and then carefully diluted cell extracts are prepared
for ﬂuorometric assay of UNG2 activity (17). Assuming full
equilibration of the inhibitor across the cell membrane, and
taking into account extract dilutions and measured cell
Table 1. Crystallographic data collection and refinement statistics
Space group P212121
Cell dimensions a ¼ 43.2, b ¼ 69.1 and c ¼ 70.4 s
Resolution range (A ˚) 49.3–1.3
Rsym (Last shell)
a 0.06 (0.49)
Completeness (Last shell) 98.0 (92.4)%
Multiplicity (Last shell) 4.9 (4.2)
I/s(I) (Last shell) 10.2 (2.6)
Number of reflections 51470
Refinement
F Data cutoff in s (F) units 0
Number of atoms Average B (A ˚ 2)
Protein 1808 11.1
Solvent 315 21.0
Ligand 25 13.8
Total 2148 12.6
R-value 0.18
Rfree (test set of 5%) 0.21
Stereochemical constraints
Bond length rms (A ˚) 0.007
Bond angles rms (degrees) 1.26
Improper angles rms (degrees) 0.07
aRsym ¼
P
h
P
j jIhj  h Ihij=
P
h
P
j jIhjj, where h represents a unique reflec-
tion and j means symmetry equivalent indices, I is the observed intensity, and
<I> is the mean value of I.
Figure 4. Structure of inhibitory compounds identified from high-throughput
screening. IC50 values were determined for each purified compound and a full
mode-of-inhibition analysis and structural characterization was performed for
compound 1. The IC50 value for compound 1 is equivalent to its true Ki.
Figure 5. Inhibition by 1. (A) Concentration dependence of inhibition. The
curve is a nonlinear least-squares fit to Equation 1 (IC50 ¼ 9±1mM).
(B) Mode-of-inhibition analysis for compound 1. Linear competitive
inhibition was observed: Ki ¼ 6±1mM.
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UNG2 assay was calculated to be 13 mM (Figure 3). This
concentration consistently gave rise to 20 ± 4% inhibition
of UNG2 activity relative to control extracts prepared ident-
ically and in parallel, which is <70% inhibition expected from
a competitive inhibitor with a Ki ¼ 6 mM. This difference
may reﬂect that (i) 1 is poorly membrane permeable, or
(ii) that 1 is not metabolically stable in the intracellular envi-
ronment. In this respect, oximes are known to be reduced by
microsomal NADH cytochrome b5 reductase (24,25).
To evaluate the structural basis for inhibition, UNG2 was
cocrystallized with 1 and diffraction data were collected to
1.3 s resolution and reﬁned to an Rfactor and Rfree of 0.19
and 0.22, respectively (PDB ID 2HXM, Figure 6A). In con-
trast to damaged DNA binding, which leads to a contraction
of the active site structure (15) (26), binding of 1 led to only
minor structural changes as compared to uncomplexed UNG2
(pdb code 1AKZ), with an r.m.s. deviation over 221 C-a
atoms of only 0.58 s. Despite the differences in induced ﬁt
binding as compared to damaged DNA, 1 remarkably shares
many of the binding interactions observed in the uracilated-
DNA complex (Figure 6B and C). The DNA binding site of
UNG2 is composed of a uracil recognition pocket ﬂanked by
a deep groove which is predominantly involved in accommo-
dating the single strand of DNA that contains the extrahelical
uracil. In the DNA complex, speciﬁc hydrogen bonding and
aromatic stacking interactions with the extrahelical uracil
involving Asn204, His268, Gln144 and Phe158 are observed
(Figure 6B). In addition, UNG2 also makes important interac-
tions via neutral and charged hydrogen bonds with the 50 and
30 phosphodiester groups of the deoxyuridine and the 30
phosphodiester group of the 30 adjacent nucleotide using the
g-hydroxyls of Ser169, Ser270 (data not shown) and Ser247,
respectively (Figure 6B). The uracil base of 1 shares the
uracil interactions seen with the uracilated-DNA complex,
with the exception of the catalytically important short hydro-
gen bond between uracil O2 and His268 (16,27,28). The
planar oxime linkage at the uracil side of the tether is
observed to extend directly over the space that is occupied
by the deoxyribose ring of deoxyuridine in the DNA com-
plex, but then, the alkane linker sharply kinks such that the
oxime linkage connecting to the benzylformate moiety nearly
perfectly superimposes the path taken by the sugar phosphate
backbone of the DNA 30 to the deoxyuridine nucleotide
(Figure 6C). This trajectory of the linker presents the car-
boxylate substituent of the benzyl ring such that it forms a
charged tridentate hydrogen bond with the backbone amide
groups of Ser247 and Tyr248 and the g hydroxyl of Ser247
(Figure 6B). These interactions with the carboxylate group
mimic those of the 30 phosphodiester group of the nucleotide
directly adjacent to deoxyuridine in the DNA complex
(Figure 6C). In addition, the oxime oxygen on the uracil
side of the tether accepts a hydrogen bond from the
g-hydroxyl of Ser169 thereby mimicking the interaction of
the 50-phosphate of dUrd in the DNA complex. Due to differ-
ences in induced ﬁt binding between 1 and uracilated-DNA,
the catalytic His268 is too far from uracil O2 to form the
strong hydrogen bond seen in the DNA complex. Instead,
His268 stacks over the benzyl ring of 1 to form a 3.6 s
p–p aromatic interaction (Figure 6B). Overall, 1 shares
three of the four hydrogen bond interactions with the uracil
base observed in the DNA structure and three of the ﬁve
DNA backbone hydrogen bonds.
This structure also provides useful insights into the inhibi-
tion provided by compound 2, as well as our previously
Figure 6. Interactions of 1 and damaged DNA with the active site of UNG2.
(A) Global structure of inhibitor-UNG2 complex. (B) Discrete interactions of
1 with the active site of UNG2. The 2Fo–Fc electron density map is shown at a
contour level of 1s.( C) Overlay of 1 (gold) with the region of the damaged
DNA strand (turquoise) containing uracil and the adjacent two 30 nt (1EMH).
Nucleic Acids Research, 2006, Vol. 34, No. 20 5877characterized tight-binding SFT compound (3, Ki ¼ 300 nM)
that contains a 2,4,5-trihydroxybenzyl substituent (17).
Manual docking studies suggest that the longer three car-
bon linker of 2 is used to extend its m-formate substituent
such that it can serve as a DNA phosphate mimic as observed
for the p-formate substituent of 1. Our previously reported
tight-binding SFT compound contained a p-hydroxyl sub-
stituent and also a linker that is one carbon longer than 1 sug-
gesting that the p-hydroxyl is positioned to form neutral
hydrogen bonding interactions in the same pocket occupied
by the p-formate group of 1. Apparently, the 20-fold higher
afﬁnity of this previous SFT ligand arises from favorable pre-
sentation of all of its hydroxyl substituents. It is interesting to
note that the 215 member aldehyde SFT library contains only
two carboxylate compounds, and both of these were detected
as inhibitors in HTS when the correct linker length was
employed (i.e. compounds 1 and 2). Thus, binding elements
possessing molecular features similar to the DNA substrate
arise more frequently as inhibitors, suggesting that libraries
enriched in such motifs might have higher hit rates.
The SFT approach may ﬁnd general utility in targeting
enzymes that recognize extrahelical bases. The ﬂexible
alkane tether appears to be an accommodating scaffold that
allows favorable presentation of binding elements that are
complementary to the DNA binding surface of the enzyme.
More generally, substrate fragments (or weak binding lig-
ands) that target enzyme active sites should make excellent
starting places for rapid inhibitor development by this or
other tethering approaches (29).
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